Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk.
- Conditions
- Subjects 55 years of age and older with Albuminuria (AER: 20 700 i'g/min) and other protocol specified cardiovascular risk factors will be randomised. Subjects must be on a stable dose of ACE-I treatment equivalent to 5 mg or more of Ramipril for 2 months prior to the Day 1 visit (screening/enrolment).MedDRA version: 6.1Level: SOCClassification code 10047065
- Registration Number
- EUCTR2004-000022-75-IT
- Lead Sponsor
- BRISTOL-M.SQUIBB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method